In recent years, both the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) have emphasized the importance of personalized medicine in the treatment of advanced ovarian cancer, particularly concerning the use of PARP inhibitors. This evidence concerns the gene PARP1 and ovarian carcinoma.